iBio, Inc. IBIO
0.79 USD +0.05 (+6.96%)
Nov 9, 2026, 11:47 AM EST
0.75 Day range 0.8166
0.69 52-week range 3.82
- YTD
- -59.07%
- 1 year
- -40.15%
News
globenewswire.com iBio to Participate in Upcoming Investor Conferences SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
benzinga.com Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human…
benzinga.com This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
benzinga.com HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
benzinga.com iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approachWhen combined with semaglutide, IBIO-610 drove…
benzinga.com Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5 Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.
benzinga.com iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing…
benzinga.com iBio Q3 EPS $(0.07) Misses $(0.06) Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 85.71 percent increase over losses of $(0.49) per…- benzinga.com iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026 iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday,…
- benzinga.com iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate…
- benzinga.com Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7 Jones Trading analyst Catherine Novack initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
- benzinga.com iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program On February 27, 2026, iBio, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale AgreementSM (the "ATM Agreement") with Jefferies LLC ("Jefferies") providing for the sale by…
- benzinga.com iBio Files Preliminary Prospectus To Issue Up To $200M In Securities The information contained in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is…
benzinga.com iBio Earnings Review: Q2 Summary - benzinga.com iBio Q2 EPS $(0.09) Misses $(0.07) Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 81.25 percent increase over losses of $(0.48) per…
benzinga.com iBio Files Prospectus For Resale Of 11,061,738 Shares Of Common Stock By Selling Stockholders 11,061,738 Shares of Common StockThis prospectus relates to the resale from time to time of up to 11,061,738 shares of common stock, par value $0.001 per share (the "Common Stock") of iBio, Inc. (the…- benzinga.com iBio Announces Private Placement Of Approximately $26M The financing was led by Frazier Life Sciences and included participation from other existing investors.iBio intends to use the net proceeds received from the offering to advance its preclinical…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com iBio Q1 EPS $(0.11) Misses $(0.10) Estimate, Sales $100.000K Beat $25.000K Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 7.84 percent. This is a 76.09 percent increase over losses of $(0.46) per…
benzinga.com iBio Announces New Preclinical Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate Supported By Preclinical Data Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Did iBio Shares Surge Over 11% In Pre-Market Trading? iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com US Stocks Mixed; Coca-Cola Posts Upbeat Earnings 
benzinga.com This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
benzinga.com Oppenheimer Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5 Oppenheimer analyst Jay Olson initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday 
benzinga.com This Kontoor Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - benzinga.com Leerink Partners Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $2 Leerink Partners analyst Roanna Ruiz initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $2.
benzinga.com Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com iBio Announces Preclinical Data In Which An Engineered Amylin Receptor Agonist Antibody Reduced Acute Food Intake In A Mouse Model Of Obesity By 60%, Equivalent To The Reduction In Food Intake From A Clinically Advanced Dual Amylin And Calcitonin Receptor Agonist Peptide (67%). Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonistFindings support…
benzinga.com Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket